Q2false--12-3100018304872023-06-300001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-01-012022-12-310001830487phvs:NonclinicalExpensesMember2022-01-012022-06-300001830487phvs:PersonnelExpensesMember2022-01-012022-06-300001830487phvs:PharvarisGmbhMember2022-01-012022-06-300001830487ifrs-full:RetainedEarningsMember2022-01-012022-06-300001830487phvs:PharvarisNetherlandsBvMember2022-01-012022-06-300001830487phvs:RestrictedStockUnitsMember2022-12-310001830487ifrs-full:OtherReservesMember2022-01-012022-06-300001830487phvs:PrivatePlacementsMemberifrs-full:OrdinarySharesMember2023-01-012023-06-300001830487phvs:PharvarisHoldingsBvMember2022-01-012022-06-300001830487phvs:ManufacturingCostsMember2023-01-012023-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-06-300001830487ifrs-full:RetainedEarningsMember2022-06-300001830487ifrs-full:GrossCarryingAmountMember2022-12-310001830487ifrs-full:OtherReservesMember2023-06-3000018304872023-03-012023-03-010001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-12-3100018304872022-06-300001830487phvs:OtherAccruedLiabilitiesMember2023-06-3000018304872023-01-012023-03-310001830487phvs:PreclinicalAccruedLiabilitiesMember2022-12-310001830487phvs:PharvarisIncMember2022-01-012022-06-300001830487ifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001830487phvs:PersonnelRelatedAccrualsMember2023-06-300001830487phvs:BlackScholesFormulaMember2023-04-062023-04-060001830487phvs:SVBLeerinkMember2023-01-012023-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-01-012023-06-300001830487phvs:PersonnelExpensesMember2023-04-012023-06-300001830487ifrs-full:OtherReservesMember2021-12-310001830487ifrs-full:OrdinarySharesMemberphvs:SVBLeerinkMember2023-01-012023-06-3000018304872022-01-012022-06-3000018304872023-02-012023-02-010001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-06-300001830487phvs:RestrictedStockUnitsMemberphvs:EmployeesMember2023-01-012023-06-300001830487phvs:OtherAccruedLiabilitiesMember2022-12-310001830487ifrs-full:IssuedCapitalMember2022-06-300001830487phvs:IntellectualPropertyCostsMember2022-04-012022-06-300001830487ifrs-full:OrdinarySharesMember2022-06-300001830487phvs:ManufacturingCostsMember2022-01-012022-06-300001830487phvs:ClinicalExpensesMember2022-04-012022-06-3000018304872023-01-012023-06-300001830487phvs:PreclinicalAccruedLiabilitiesMember2023-06-300001830487phvs:ManufacturingCostsMember2023-04-012023-06-300001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-01-012023-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-06-300001830487ifrs-full:GrossCarryingAmountMember2023-01-012023-06-3000018304872023-04-032023-04-030001830487phvs:ClinicalExpensesMember2022-01-012022-06-300001830487phvs:PersonnelRelatedAccrualsMember2022-12-310001830487phvs:ManufacturingAccruedLiabilitiesMember2022-12-3100018304872022-12-310001830487ifrs-full:RetainedEarningsMember2023-06-300001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-06-300001830487ifrs-full:RetainedEarningsMember2022-12-310001830487ifrs-full:SharePremiumMember2022-01-012022-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001830487phvs:NonclinicalExpensesMember2022-04-012022-06-300001830487phvs:ManufacturingCostsMember2022-04-012022-06-3000018304872022-04-012022-06-300001830487phvs:ConsultingProfessionalAndAuditLiabilityMember2022-12-310001830487phvs:PharvarisIncMember2023-01-012023-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMemberphvs:RestrictedStockUnitsMember2023-01-012023-06-300001830487phvs:OfficeLeaseMember2022-12-310001830487phvs:ManufacturingAccruedLiabilitiesMember2023-06-3000018304872022-01-012022-12-310001830487ifrs-full:GrossCarryingAmountMember2023-06-300001830487ifrs-full:PreferenceSharesMember2023-06-300001830487ifrs-full:OtherReservesMember2022-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMemberphvs:StockOptionsMember2023-01-012023-06-300001830487phvs:ClinicalAccruedLiabilitiesMember2023-06-300001830487phvs:PharvarisNetherlandsBvMember2023-01-012023-06-300001830487ifrs-full:OrdinarySharesMember2022-12-310001830487ifrs-full:RetainedEarningsMember2021-12-310001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-12-310001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2023-06-300001830487phvs:PharvarisHoldingsBvMember2023-01-012023-06-300001830487ifrs-full:OtherReservesMember2022-12-310001830487ifrs-full:IssuedCapitalMember2022-01-012022-06-300001830487phvs:PersonnelExpensesMember2022-04-012022-06-300001830487phvs:IntellectualPropertyCostsMember2023-01-012023-06-3000018304872023-06-3000018304872023-04-062023-04-060001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2022-12-310001830487phvs:RestrictedStockUnitsMember2023-01-012023-06-300001830487phvs:ClinicalExpensesMember2023-01-012023-06-300001830487ifrs-full:SharePremiumMember2022-12-310001830487ifrs-full:SharePremiumMember2023-06-300001830487phvs:ConsultingProfessionalAndAuditLiabilityMember2023-06-300001830487phvs:NonclinicalExpensesMember2023-01-012023-06-300001830487phvs:ClinicalAccruedLiabilitiesMember2022-12-310001830487ifrs-full:IssuedCapitalMember2023-06-300001830487phvs:PersonnelExpensesMember2023-01-012023-06-300001830487phvs:IntellectualPropertyCostsMember2023-04-012023-06-300001830487ifrs-full:SharePremiumMember2023-01-012023-06-3000018304872023-05-012023-05-010001830487phvs:OfficeLeaseMember2023-06-300001830487phvs:PrivatePlacementsMember2023-06-012023-06-300001830487phvs:StockOptionsMember2023-06-300001830487phvs:IntellectualPropertyCostsMember2022-01-012022-06-300001830487phvs:ClinicalExpensesMember2023-04-012023-06-300001830487ifrs-full:SharePremiumMember2022-06-3000018304872023-04-012023-06-300001830487ifrs-full:IssuedCapitalMember2022-12-310001830487phvs:NonclinicalExpensesMember2023-04-012023-06-300001830487phvs:StockOptionsMember2022-12-310001830487phvs:StockOptionsMember2023-01-012023-06-300001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-12-310001830487phvs:PrivatePlacementsMemberifrs-full:OrdinarySharesMember2023-06-300001830487phvs:BlackScholesFormulaMember2023-04-060001830487ifrs-full:OtherReservesMember2023-01-012023-06-300001830487ifrs-full:OrdinarySharesMember2023-06-3000018304872021-12-310001830487ifrs-full:RetainedEarningsMember2023-01-012023-06-300001830487ifrs-full:SharePremiumMember2021-12-310001830487phvs:RestrictedStockUnitsMember2023-06-300001830487ifrs-full:OrdinarySharesMemberphvs:SVBLeerinkMember2022-01-012022-03-310001830487phvs:PharvarisGmbhMember2023-01-012023-06-300001830487ifrs-full:IssuedCapitalMember2023-01-012023-06-300001830487ifrs-full:IssuedCapitalMember2021-12-310001830487ifrs-full:GrossCarryingAmountMember2021-12-31iso4217:EURiso4217:USDxbrli:sharesxbrli:purexbrli:sharesiso4217:EURxbrli:sharesiso4217:USDutr:Yphvs:Staff
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2023
Commission File Number: 001-40010
Pharvaris N.V.
(Translation of registrant’s name into English)
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
PHARVARIS N.V.
On August 7, 2023, Pharvaris N.V. (the "Company") issued a press release reporting financial results and other business updates for the three and six months ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act. The Company is also updating certain of its Risk Factors that were previously included in Item 3.D. of its Annual Report on Form 20-F, which updated Risk Factors are attached to this Form 6-K as Exhibit 99.4. Exhibits 99.2, 99.3 and 99.4 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-263198) and Form S-8 (Registration Number 333-252897) of Pharvaris N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
PHARVARIS N.V. |
|
|
Date: August 7, 2023 |
By: |
/s/ Berndt Modig |
|
Name: |
Berndt Modig |
|
Title: |
Chief Executive Officer |
